FDA approves Pfizer and Moderna booster doses, authorizes mix and match for COVID-19 vaccines
Author
Blaire Bryant
Upcoming Events
Related News
Key Takeaways
On October 21, the Centers for Disease Control and Prevention (CDC) endorsed the use of Moderna and Johnson & Johnson booster shots following a recommendation from the Advisory Committee on Immunization Practices’ (ACIP). The endorsement follows the Food and Drug Administration’s (FDA) October 20 announcement approving the emergency use of booster doses for both vaccines.
The CDC also endorsed the use of heterologous (mix and match) COVID-19 vaccine booster shots, following FDA approval based on safety and efficacy data. Eligible individuals will be able to select their booster dose from any of the FDA endorsed or approved COVID-19 vaccines.
Updated guidelines for the use of a COVID-19 vaccine booster dose are as follows:
- Johnson & Johnson COVID-19 vaccine: A single booster dose may be administered at least two months after completion of the single-dose primary regimen to individuals 18 years of age and older.
- Moderna COVID-19 vaccine: A single booster dose may be administered at least six months after completion of the primary series to individuals that are 65 years of age and older, 18 through 64 years of age at high risk of severe COVID-19, or 18 through 64 years of age with frequent institutional or occupational exposure to COVID-19.
- Pfizer-BioNTech COVID-19 vaccine: A single booster dose may be administered at least six months after completion of the primary series to individuals 18 through 64 years of age with frequent institutional or occupational exposure to SARS-CoV-2.
As key providers of local public health services and frontline service providers for the medically vulnerable, counties have supported over 190 million vaccinations in the U.S. to date and will continue to play an essential role in the administration of COVID-19 vaccines and boosters. For more information on how county health facilities can prepare for the distribution of COVID-19 boosters, see the “Vaccine Booster Readiness Checklist for County Health Facilities” tab in NACo’s COVID-19 Vaccine Distribution Toolkit.
ADDITIONAL RESOURCES
Resource
COVID-19 Vaccine Toolkit for Counties
Related News
CMS announces new funding opportunity for the Innovation in Behavioral Health Model
On October 16, the Centers for Medicare & Medicaid Services (CMS) released a Notice of Funding Opportunity (NOFO) for Cohort II of the Innovation in Behavioral Health (IBH) Model. This new round of funding builds on the initial IBH model announced in 2024 and continues CMS’s efforts to improve outcomes for individuals with moderate to severe mental health conditions and substance use disorders (SUDs) by advancing integration between behavioral and physical healthcare.
Michelle Alyssa Go Act reintroduced in the 119th Congress, a critical step for county behavioral health systems
On September 18, the Michelle Alyssa Go Act was reintroduced in the U.S. House of Representatives. This bipartisan legislation aims to increase the number of federal Medicaid-eligible in-patient psychiatric beds from 16 to 36, providing critical support for individuals seeking treatment for mental health and substance use disorders.
Congress passes SUPPORT Act reauthorization
On September 18, the U.S. Senate passed the SUPPORT for Patients and Communities Reauthorization Act of 2025 (SUPPORT Act Reauthorization) (H.R. 2483) by voice vote, following House passage earlier this year. With strong bipartisan backing in both chambers, the legislation now heads to the President’s desk for signature.